Radio-immunothérapie du lymphome folliculaire: un pas vers la guérison [Radioimmunotherapy of follicular lymphoma: a step towards cure?]

Détails

ID Serval
serval:BIB_86BDF15B8BF8
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Radio-immunothérapie du lymphome folliculaire: un pas vers la guérison [Radioimmunotherapy of follicular lymphoma: a step towards cure?]
Périodique
Bulletin du cancer
Auteur(s)
Ketterer N., Bischof Delaloye A., Helg C., Luthi F., Buchegger F.
ISSN
1769-6917[electronic]
Statut éditorial
Publié
Date de publication
2007
Volume
94
Numéro
9
Pages
799-806
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review - Publication Status: ppublish
Résumé
Advanced stage follicular lymphoma is incurable by conventional treatment. Important progress has been observed with the development of new therapies based on monoclonal antibodies and on the use of radioimmunotherapy (RIT) in the treatment of non-Hodgkin lymphomas (NHL). Rituximab in combination with chemotherapy in the upfront setting significantly improved treatment outcome as compared with chemotherapy alone. Different studies also indicate that RIT has an important role in the management of NHL and could be beneficial in combination with chemotherapy. These two new treatment options have clearly distinctive mechanisms of action, rituximab being an exclusively biological treatment and RIT adding targeted systemic radiation therapy. Both RIT and the unlabeled antibody treatments might be further improved by different strategies including repetition of RIT or combination of different antibodies. We present here our experience with RIT using 131I-tositumomab (Bexxar) and discuss different topics regarding RIT, like the use of different antibodies, the best choice of the radioisotope or the place of radio-imaging. From the therapeutic point of view, we argue that the debate should not be as to which one among antibody immunotherapy or RIT should be best added to chemotherapy, but that all three treatments might be optimally combined with the aim to get the highest chance of cure for advanced stage follicular lymphoma.
Mots-clé
Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow Diseases, Clinical Trials as Topic, Combined Modality Therapy, Humans, Lymphoma, Follicular, Mice, Radioimmunotherapy, Radiometry, Radiopharmaceuticals, Radiotherapy Dosage, Treatment Outcome
Pubmed
Web of science
Création de la notice
25/01/2008 11:21
Dernière modification de la notice
20/08/2019 14:46
Données d'usage